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Abstract 
Purpose 
In randomised clinical trials (RCTs) the selection of appropriate outcomes is crucial to the 
assessment of whether one intervention is better than another. The purpose of this review is 
to identify different clinical outcomes reported in glaucoma trials. 
Methods 
We conducted a systematic review of glaucoma RCTs. A sample or selection of glaucoma 
trials were included bounded by a time frame (between 2006 and March 2012). Only studies 
in English language were considered.  All clinical measured and reported outcomes were 
included.  The possible variations of clinical outcomes were defined prior to data analysis. 
Information on reported clinical outcomes was tabulated and analysed using descriptive 
statistics.  Other data recorded included type of intervention and glaucoma, duration of the 
study, defined primary outcomes, and outcomes used for sample size calculation, if 
nominated.   
Results 
The search strategy identified 4323 potentially relevant abstracts. There were 315 
publications retrieved, of which 233 RCTs were included.  A total of 967 clinical measures 
were reported. There were large variations in the definitions used to describe different 
outcomes and their measures.  Intraocular pressure (IOP) was the most commonly reported 
outcome (used in 201 RCTs, 86%) with a total of 422 measures (44%). Safety outcomes 
were commonly reported, in 145 RCTs (62%) whereas visual field outcomes were utilised in 
38 RCTs (16%).  
Conclusions 
There is a large variation in the reporting of clinical outcomes in glaucoma RCTs.  This lack 
of standardisation may impair the ability to evaluate the evidence of glaucoma interventions. 
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Introduction 
Randomised controlled trials (RCTs) represent the gold standard for gathering evidence 
about treatment effectiveness. Clinical trials seek to evaluate whether an intervention is 
effective and safe by comparing the effects of different alternatives on outcomes that are 
chosen to identify its benefits and harms. There is recognition that insufficient attention has 
been paid to the selection of proper outcomes to be used in clinical trials. Outcomes need to 
be relevant to patients, clinicians and policy-makers if the research is to influence 
practice.(1) A variety of outcomes can be selected for clinical trials, and these can be 
measured and reported in different ways. Problems arise if the selection, measurement and 
reporting of outcomes are inconsistent across clinical trials. First, important outcomes can be 
overlooked. If trialists are not aware of the importance of outcomes, it is likely that factors 
relating to the conduct of the trial, such as sample size, will determine which outcomes are 
measured.(2)  A lack of standardisation may also lead to inefficient trials that involve multiple 
outcomes, larger than required sample sizes and multiple interpretations of results.(3)  
Secondly, meta-analysis will be difficult if different outcomes have been used. Even if the 
same outcomes are selected, they may be measured and analysed in different ways, and 
this too can impair the ability to synthesise their results. Finally, the third problem is selective 
outcome reporting bias (SORB) defined as the results-based selection for publication of a 
subset of the original measured outcome variables (4); in the absence of a set of core 
outcomes, trialists may decide to omit certain results from the final report.(2) Missing 
outcome data can affect systematic review in two ways. Publication bias, where a study is 
not published on the basis of its results, can lead to bias in the analysis of a particular 
outcome. Whereas, in a published study that has been identified by the reviewer, SORB can 
arise if the outcome had been measured and analysed but not reported.(5) The selection of 
appropriate outcomes in a trial, therefore, is crucial to the assessment of whether one 
intervention is better than another.  One way to address these issues is the development of 
agreed standardised sets of outcomes, known as ‘core outcome sets’ (COS).(6) Some work 
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has been undertaken to identify and validate the different patient reported outcome 
measures used in glaucoma trials. This previous effort provided a framework (and critique of 
existing tools) for selecting the core patient reported outcomes in glaucoma studies.(7) 
However, no attempt has been undertaken on the standardisation of the clinical outcome 
measures in glaucoma RCTs. Therefore, as a first step towards this goal, we aim to identify 
the breadth of clinical outcomes reported in glaucoma RCTs. 
Methods 
We conducted a systematic review of RCTs in glaucoma between January 2006 and March 
2012. The reason of the time frame was that we were aiming to retrieve approximately 200 
RCTs and we chose to start our search from the most recent ones. The n=200 is an arbitrary 
number that we proposed would be sufficient to identify the variation on outcomes reported 
in glaucoma RCTs. We searched for RCTs in glaucoma published in English only due to 
resources constraints; however there were no restrictions on the population studied, applied 
interventions, phases of the trials, or types of glaucoma. 
The following electronic databases were searched: Ovid MEDLINE (R) In-Process & Other 
Non-Indexed Citations and Ovid MEDLINE (R) from January 2006 to first week of March 
2012. A sensitive search strategy with both controlled subject headings and text terms 
relating to glaucoma and randomised controlled trials was run. The abstracts were graded as 
“included”, “possible” or “excluded”. Abstracts were excluded if they were not evaluating 
glaucoma patients and/or the study design was not an RCT or not in English language. The 
investigators planned to identify further relevant RCTs (original studies) from references of 
the retrieved articles.  All abstracts were reviewed independently by one reviewer (RI). 
Another senior investigator (AAB) reviewed approximately 10% of all abstracts (400 
consecutive abstracts) to evaluate agreement. This was a pragmatic approach that would 
have resulted in a larger duplicate grading if the agreement had been suboptimal.  
Regarding the assessment of eligibility of RCTs full text copies were assessed by one 
reviewer (RI).  A second masked senior reviewer (AAB) reviewed 10 consecutive papers. 
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All clinical outcomes and variations of reporting were included in the analysis.  We collected 
information on population, duration of follow up (months), sample size, type of intervention 
(medical, surgical, laser, others) and outcomes. We recorded which outcomes were 
considered to be primary or secondary and documented methods used to measure them, by 
whom, and when they were measured and analysed. Other types of outcomes such as 
patient reported outcome measures (PROMs), pharmacokinetic evaluation as well as 
economic outcomes were excluded. We agreed to contact trial authors as needed to clarify 
any details necessary to make a complete assessment of the study. 
The data were initially abstracted on “Microsoft Office Access 2007” database and then 
statistics was run on Excel database.  The data were tabulated in an excel sheet (Microsoft 
Corporation, Redmond, WA). Comprehensive pilot testing with two investigators (a clinician 
(RI) and a glaucoma expert (AAB)) was undertaken. As an effect, taxonomy of glaucoma 
outcomes was developed. Outcomes were grouped into one of eight main outcomes: 
intraocular pressure (IOP), visual field (VF), safety, haemodynamics, anatomical, aqueous 
humor (AH) dynamics, surgical-related, and persistence/ adherence to therapy. 
Outcomes were further classified into different measures (specific measurement, specific 
metric or methods of aggregation). For example, for IOP, the pre-defined measures were: (1) 
IOP level, which was further subclassified into three possible measurements (Table), (2) IOP 
change from baseline, which was also subclassified according to the methodology of 
measurement, (3) composite definition of success/failure using IOP as part of the definition, 
where three different measures were identified and (4) other descriptions of IOP outcomes 
as in correlations / associations using IOP (Table). 
The pre-defined measures for the VF were: (1) evidence of progression of the VF, which was 
further subdivided into different metrics according to the methodology of measurement, (2) 
rate of VF progression/slope and (3) time to VF progression, which was also classified 
according to the methodology used.  A similar classification of measures was used for the 
other clinical outcomes (see supplementary Table S1 (web only file) for classification). 
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Designated primary and secondary outcomes were also identified. Descriptive statistical 
analysis was undertaken.  
Results 
The search identified 4323 potentially relevant abstracts. Of these, 238 abstracts were 
retrieved as “include” and 56 retrieved as “possible”.  From these abstracts two hundred and 
fifteen articles were included whereas 79 articles were excluded because either the study 
was not an RCT or it was an RCT but not for a glaucoma intervention. An additional 24 
potential RCTs identified from the references with three of these were excluded for not being 
an RCT. These RCTs covered the period between 1988 and 2005 as regards recruiting 
participants, e.g. AGIS recruiting period ranged from 1988 to 1992.(8) Two hundred and 
thirty three full articles were finally included for data synthesis (Figure 1, modified PRISMA 
flow chart).(9) Regarding abstract selection there was one disagreement between the two 
reviewers (0.25%), where one abstract was identified by the second reviewer (AAB) as 
“possible” which had been excluded by the first reviewer (RI). Following full text review, there 
was a disagreement between the first two reviewers to include two articles which were 
excluded by the senior reviewer (AAB). This disagreement was resolved by discussion and 
the decision was to exclude them for not being RCTs. 
A total of 967 clinical measures were reported.  There were large differences in the 
definitions used to describe different outcomes and their measures. IOP was the most 
commonly reported outcome with a total of 422 times (44% of all measures) (Table). IOP 
was reported as an outcome in 201 of the 233 RCTs (86%).  Among the IOP-related 
measures (Table), the most commonly used was mean IOP (n=143, 15% of all measures) 
while composite definition of success/failure using IOP as part of the definition (e.g., 
achieving a percentage of IOP reduction or target IOP with or without medication) was the 
second most commonly utilised (n=135, 14% of all measures) (Table). Aqueous humor 
dynamics was only reported in five of the 233 RCTs (2%). On the other hand, safety 
outcomes were reported in 145 RCTs (62 %).  There was a total of 346 times (36%) when 
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safety measures were described (Table).  Visual acuity (VA) was the commonest among the 
safety measures (n=75, 8% of all measures) (Table). On the other hand, visual field was 
utilised in 38 RCTs (16%), (reported 50 times, 5% of all measures) (table), where VF 
progression measured with global indices/score was the commonest (n=30, 3% of all 
measures) (Table). Ocular and systemic haemodynamics (reported in 32 RCTs (n=91, 9% of 
all measures), anatomical outcomes (reported in 25 RCTs) (n=34, 4% of all measures) as 
well as surgical outcomes (reported in 19 RCTs) (n=19, 2% of all measures) were measured 
and reported. Optic nerve head (ONH) morphology was the commonest among the 
anatomical-related measures (n=19, 2% of all measures) (Table). 
Systemic haemodynamics (blood pressure (BP) & pulse rate (PR) was the most commonly 
reported measure among the haemodynamics (n= 44, 5% of all measures) (Table). 
Primary outcomes were defined in 143 of the 233 RCTs (61%).  Thirty one of the 143 studies 
(21.6%) determined more than one primary outcome; the total number of primary measures 
identified was 186, with IOP-related measures being the commonest (n=135, 73% of primary 
measures) (Table).  Mean IOP/ mean diurnal IOP/ 24-hour IOP was the commonest to be 
used as primary measure (n=51, 27% of all primary measures) (Table).  
Discussion 
To the best of our knowledge, this is the first study to describe the selection of clinical 
outcomes in glaucoma RCTs. The study demonstrated a large variation in the way clinical 
outcomes were reported and a total lack of standardisation which may impair the ability to 
robustly evaluate the evidence of glaucoma interventions. 
This variation was greatest for IOP and safety measures, the most commonly used clinical 
outcomes. Even though VF tests were uncommonly utilised as an outcome, a diversity of 
measurements was also apparent (with 12 different ways of evaluating VFs), whereas 
persistence/adherence to therapy has never been reported as an outcome.  
Whilst the review was conducted in a rigorous, systematic manner, it is possible that some 
studies may have been missed by not searching the “grey” literature. The review had good 
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external validity - the studies we identified included different glaucoma populations as well as 
different interventions.  We excluded observational studies, but we were confident that these 
reports would be unlikely to add to the breadth of outcomes observed in this review.  
Although the search for RCTs covered the period between January 2006 till March 2012, 
original reports of the included RCTs had covered the period between 1988 and 2005 as 
regards to study design and recruiting participants.(8) (10-13) However, we acknowledge the 
potential limitations of time frame and language restrictions. We acknowledge that different 
clinical trials may have different objectives that lead to variation in primary outcomes.  Phase 
I and II trials might be most concerned with effects on IOP and later phase trials might be 
most concerned with effects on visual field.   However, our aim was to determine the breadth 
of utilised and reported clinical outcomes as a first step in the development of core clinical 
outcome sets for glaucoma interventions. A Delphi survey is ongoing to get consensus on 
clinical outcomes and identify further clinical measures for implementation in glaucoma trials.  
The selection of appropriate outcomes is crucial when designing clinical trials in order to 
compare directly the effects of different interventions in a way that maximises evidence 
synthesis;.  There is a growing recognition that insufficient attention has been paid to the 
selection of outcomes when conducting a clinical trial.(1) Clinicians often assess glaucoma 
treatment in terms of the effect on IOP. However, being a surrogate outcome, it may be 
inappropriate to use IOP as the sole consideration for the evaluation of a glaucoma 
intervention; (14) besides there are different ways of evaluating IOP changes. In the 
published literature over a 5-year period (between 2001-2005), Rotchford et al identified 
variation in reporting of IOP success rates in glaucoma surgical trials. The authors 
concluded that there were nearly as many different IOP-related deﬁnitions of success after 
glaucoma surgery as there were articles on the subject, and more than 70% of deﬁnitions 
appeared in only a single article.(15) The authors recommended that standardisation of 
published outcome parameters is essential to allow meaningful comparisons between 
different study reports.(15) 
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The outcomes reported by studies are the key for clinicians when making decisions about 
health care; however there is a general lack of consensus regarding the selection of 
outcomes in clinical settings, which affects trial design, analysis, as well as reporting.(16) 
Measuring outcomes that will not change healthcare decisions leads to a waste of resources 
and a failure to capitalise on the potential power of research to improve health care.(4) 
The difficulties caused by differences in outcome measurement are well known to systematic 
reviewers. For instance, the five most accessed and top cited Cochrane Reviews in 2009 all 
reported problems related to outcomes in eligible trials due to inconsistencies in the 
outcomes reported in the primary reports.(4) There is still great uncertainty on how best to 
select the most appropriate outcomes for use in a clinical trial.(17) Some of the factors 
underlying this uncertainty may include ambiguity regarding which outcomes are of 
relevance to patients, unknown performance characteristics of potential outcomes(e.g. 
reliability), or improvements in general care of patients with emergence of new technologies, 
with the result that previously used outcomes are no longer relevant.(18)  
The Core Outcome Measures in Effectiveness Trials (COMET) Initiative (19) was launched 
in January 2010 to address this lack of standardised outcomes in clinical trials and to 
develop a minimum set of measures named “core outcome sets” (COS), which include 
endpoints to be reported as a minimum.  There is an expectation that the core outcomes will 
be reported to allow the results of studies to be combined as appropriate; and that 
researchers will continue to collect other outcomes as well.(6). If the outcomes in the COS 
are reported then reviewers or people looking at studies in isolation, will always have access 
to the same set of key data.(6) 
To solve the issue of outcome heterogeneity, we aim to reach consensus on important 
clinical outcomes and how to measure the outcomes in glaucoma intervention trials by taking 
into account the views of clinicians and trialists through a Delphi survey of expert opinion 
and by implementing the COSMIN (COnsensus-based Standards for the selection of health 
Measurement Instruments) approach (20) as a final step. 
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In summary, the selection of outcomes and their measures was inconsistent among 
glaucoma RCTs.  In addition, there was a wide variety of description within individual clinical 
outcomes. There is an obvious need to define a core clinical outcome dataset for glaucoma 
trials.  
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Table legends 
Table: Clinical outcome measures identified in randomised controlled trials between 
January 2006 and March 2012 
 
Outcomes  Measures  N (%) N primary (%) 
IOP Mean IOP/Mean diurnal IOP/24 hr IOP  143(15%)   51(27%) 
 Level of IOP variation (Range/Fluctuation)  12 (1%) 3(2%) 
 Other level of IOP/ unspecified criteria  7 (1%) 2(1%) 
 Mean change of IOP/Mean diurnal IOP/Change of 24 h IOP 
(from baseline)  74 (8%) 
 
35(19%) 
 Change of IOP variation (Range/Fluctuation) from baseline  5(1%)  2(1%) 
 Other change of IOP from baseline  1(0%)  0(0%) 
 Composite definition of success/failure: IOP(with or without 
medication), target IOP, percentage reduction of IOP  135 (14%) 
 
34(18%) 
 Composite definition of success/failure: IOP after 
provocation test  6 (1%) 
 
1(1%) 
 Composite definition of success/failure: number of 
postoperative medications)  34(3%)  
 
5(3% 
 
Others ( correlations/ associations using IOP)  5 (1%) 
2(1%) 
Total  422(44%) 135(73%) 
VF VF Progression: Global indices/score (MD, PSD, CIGTS 
score, AGIS score  30 (3%) 
 
10(5%) 
 VF Progression: Point/ location analysis  10 (1%) 4(2%) 
 VF- Progression: Clinical judgement  3(0.3%)  0(0%) 
 VF Progression: Others  2 (0.2%) 0(0%) 
 Rate of VF progression: Point/Location analysis  2(0.2%)  2(1%) 
 Time to progression: Global indices/score  1(0.1%)  0(0%) 
 Time to progression: Clinical judgement  1 (0.1%) 1(1%) 
 Time to progression: Others  1(0.1%)   0(0%) 
Total  50(5%) 17(9%) 
Safety Functional outcomes (VA)  75(8%)  3(2%) 
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 Others  47(28%)  16(8%) 
Total 
 
346(36%) 19(10%) 
Haemodynamics 
Systemic Haemodynamics (BP &PR)  44(5%)  
1(1%) 
 
 Others 47(4%) 3(1%) 
Total 
 
91(9%) 4(2%) 
Anatomical ONH morphology/ RNFL  19(2%)  5(3%) 
 Others 15(2%) 1(0%) 
Total  
 
34(4%) 6(3%) 
Aqueous Humour 
dynamics 
AH dynamics 5(0%) 
 
 
1(1%) 
Surgical outcomes 
 
19(2%) 4(2%) 
Persistence/adherence 
to Therapy  
 
0(0%) 
 
0(%) 
Total Measures 
 
967 186 
Abbreviations used in table : IOP, intraocular pressure; VF, visual field;; VF, visual field; MD, mean deviation; 
PSD, pattern standard deviation, CIGTS, Collaborative Initial Glaucoma Treatment Study; AGIS, Advanced 
Glaucoma Intervention Study; TFCM, tear film confocal microscopy; OGSS, Oxford Grading System Score; VA, 
visual acuity; ERG, electroretinogram; blood pressure; PR, pulse rate; ONH, optic nerve head; RNFL, retinal 
nerve fibre layer 
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